DOCSLIB.ORG

Oral Care of the Cancer Patient Bc Cancer Oral Oncology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oral Care of the Cancer Patient Bc Cancer Oral Oncology ORAL CARE OF THE CANCER PATIENT BC CANCER ORAL ONCOLOGY – DENTISTRY MARCH 2018 Oral Care of the Cancer Patient ORAL CARE OF THE CANCER PATIENT 1. INTRODUCTION…………………………………………………………………………PAGE # 3 2. PRACTICE GUIDELINES SALIVARY GLAND DYSFUNCTION / XEROSTOMIA………………..……………… 4 ORAL MUCOSITIS / ORAL PAIN…………………………………………………….. 7 DYSGEUSIA (ALTERED TASTE)……………………………………………………..… 11 TRISMUS…………………………..………………………………………………….… 12 ORAL FUNGAL INFECTIONS………………………………..………………………… 14 ORAL VIRAL INFECTIONS…………………………………………………………….. 16 ACUTE & CHRONIC ORAL GRAFT VS. HOST DISEASE (GVHD)……………… 19 OSTEORADIONECROSIS (ORN)…………………………………………………….. 22 MEDICATION-INDUCED OSTEONECROSIS OF THE JAW (MRONJ)…………… 25 3. MANAGEMENT OF THE CANCER PATIENT………………………………………………..... 28 4. MEDICATION LIST GUIDE………………………………………………………………………. 35 5. REFERENCES………………………………………………………………………………………. 39 6. ACKNOWLEDGEMENTS/DISCLAIMER…….………………………………………………….. 41 BC Cancer - Vancouver BC Cancer - Surrey BC Cancer - Kelowna BC Cancer – Prince George 600 West 10th Avenue 19750 96th Avenue 399 Royal Avenue 1215 Lethbridge Street Vancouver, B.C. V5Z 4E6 Surrey, B.C. V3V 1Z2 Kelowna, B.C. V1Y 5L3 Prince George, B.C. V2M 7E9 Page 2 of 41 (604) 877-6136 (604) 930-4020 (250) 712-3900 (250) 645-7300 Oral Care of the Cancer Patient INTRODUCTION The purpose of this manual is to provide user-friendly, evidence-based guidelines for the management of oral side-effects of cancer therapy. This will allow community-based practitioners to more effectively manage patients in their practices. It is well known that the maintenance of good oral health is important in cancer patients, including patients with hematologic malignancies. Oral pain and/or infections can cause delays, reductions or discontinuation of life-saving cancer treatment. Poor oral health can also lead to negative impacts on a patient’s quality of life including psychological distress, social isolation and inadequate nutrition. By providing these guidelines, we hope to achieve better patient outcomes. The information contained within this manual has been collected from many resources but, most significantly, from the work of the Oral Care Section of the Multinational Association for Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO). MASCC/ISOO has continually updated and published systematic reviews of the literature on the common oral complications of cancer therapy. As new evidence emerges, these guidelines will be periodically updated. The oral side-effects that are reviewed and presented in this manual include the following: 1. Salivary Gland Dysfunction / Xerostomia 2. Oral Mucositis / Oral Pain 3. Dysgeusia (Altered Taste) 4. Trismus 5. Oral Fungal Infections 6. Oral Viral Infections 7. Acute and Chronic Oral Graft Versus Host Disease (GVHD) 8. Osteoradionecrosis (ORN) 9. Medication-Induced Osteonecrosis of the Jaw (MRONJ) In addition, general Principles in the Management of the Cancer Patient in community-based dental practice and a Medication List Guide have been included. This will help the community-based clinician offer the best possible care to their patient. Finally, it must be stated that guidelines are just that; in some topic areas, research quality is poor leading to a paucity of evidence-based guidelines. It is clinical judgment, experience and the individual patient response that ultimately determines recommended therapy. BC Cancer - Vancouver BC Cancer - Surrey BC Cancer - Kelowna BC Cancer – Prince George 600 West 10th Avenue 19750 96th Avenue 399 Royal Avenue 1215 Lethbridge Street Vancouver, B.C. V5Z 4E6 Surrey, B.C. V3V 1Z2 Kelowna, B.C. V1Y 5L3 Prince George, B.C. V2M 7E9 Page 3 of 41 (604) 877-6136 (604) 930-4020 (250) 712-3900 (250) 645-7300 Oral Care of the Cancer Patient SALIVARY GLAND DYSFUNCTION & XEROSTOMIA Salivary gland hypofunction (the objective finding of reduced salivary flow) and xerostomia (the subjective sensation of dry mouth) are often seen following high dose H&N radiotherapy and are frequently reported by patients receiving various forms of chemotherapy or resection surgeries affecting salivary glands. Dry mouth can have a very significant effect on both oral health and general quality of life. Because of decreased saliva, patients are at increased risk of dental caries, periodontal disease, oral infection, halitosis, taste disorders, oral pain, difficulties with swallowing and speech, and more at risk of premature death from aspiration pneumonia. Diminished salivary flow can also affect denture retention and cause oral tissues to be more easily traumatized. At BC Cancer, we routinely measure resting and stimulated salivary flow before the initiation of high dose H&N radiotherapy, as well as 3 months and 12 months post radiation. Similarly, we routinely measure salivary volumes at the Day 100 examination for allogeneic stem cell transplant patients as dry mouth is a consistent finding in patients with chronic oral GVHD due to T-cell mediated damage to salivary glands. Frustratingly, there are very limited strategies in prevention of salivary gland hypofunction. Management strategies have focused on meticulous oral hygiene, topical fluoride and remineralizing rinses and pastes, oral lubricant gels and sprays and the use of sialagogue medications. Maintaining the patient’s dentition after high dose radiotherapy is of paramount importance due to the risk of jaw necrosis should teeth need to be removed after radiotherapy. As importantly, healthy teeth and tissues add greatly to the patient’s quality of life and ability to maintain adequate nutrition. PREVENTION STRATEGIES As mentioned, nothing has ever been shown to predictably prevent radiotherapy-induced salivary gland hypofunction. However, newer 3-dimensional radiotherapy delivery techniques (such as IMRT, VMAT and stereotactic radiotherapy) have shown great potential in preventing severe post-treatment oral dryness. BC Cancer - Vancouver BC Cancer - Surrey BC Cancer - Kelowna BC Cancer – Prince George 600 West 10th Avenue 19750 96th Avenue 399 Royal Avenue 1215 Lethbridge Street Vancouver, B.C. V5Z 4E6 Surrey, B.C. V3V 1Z2 Kelowna, B.C. V1Y 5L3 Prince George, B.C. V2M 7E9 Page 4 of 41 (604) 877-6136 (604) 930-4020 (250) 712-3900 (250) 645-7300 Oral Care of the Cancer Patient MANAGEMENT STRATEGIES Conservative management: o Frequent sips of water o Following general nutritional strategies discussed below o The use of various oral wetting agents such as moisturizing gels, mouthwashes and sprays. These products are available over the counter at most pharmacies. o Biotene and Oral Science are two companies that make a wide range of dry mouth relief products. o Sugar free mints and chewing gums: Some patients report transient relief from dry mouth by using xylitol-based products which can be ingested as a dissolvable mint, lozenge or chewing gum. Xylitol is a natural sugar that can not be metabolized by cariogenic bacteria to produce acidic by-products. Its presence alters oral bacteria environment while decreasing caries risk. Pharmaceutical management: Sialagogue medications have been used widely for patients with chronic and symptomatic oral dryness: o Pilocarpine (Salagen) – 5 mg t.i.d o Cevimeline (Evoxac) – 30 mg t.i.d o Anetholtithion (Sailor) – 25 mg t.i.d o Bethanacol – 25 mg t.i.d Side-effects of these medications are not uncommon and may include headache, sweating, nausea, runny nose, increased urination and blurring of vision. Therefore, it is recommended that the dose be increased slowly over time to allow the patient to adjust to any side-effects. It should be noted that since drug costs are high and that benefits are not long-term and decline after cessation of therapy. These drugs therefore tend to be ineffective and/or impractical long-term management strategies for patients with dry mouth. GENERAL NUTRITIONAL MANAGEMENT STRATEGIES o Add extra moisture to foods by adding sauces, gravies, butter, dressings, broth or other liquids BC Cancer - Vancouver BC Cancer - Surrey BC Cancer - Kelowna BC Cancer – Prince George 600 West 10th Avenue 19750 96th Avenue 399 Royal Avenue 1215 Lethbridge Street Vancouver, B.C. V5Z 4E6 Surrey, B.C. V3V 1Z2 Kelowna, B.C. V1Y 5L3 Prince George, B.C. V2M 7E9 Page 5 of 41 (604) 877-6136 (604) 930-4020 (250) 712-3900 (250) 645-7300 Oral Care of the Cancer Patient o Soft, mild-tasting food is often better tolerated in the dry mouth environment o Frequent sips of cold water or dissolving ice chips in the mouth may provide significant oral comfort o Avoid highly acidic foods, foods high in sugar, caffeine and alcohol Objective salivary gland hypofunction and subjective xerostomia are common long-term side-effects of high dose H&N radiotherapy and are less frequently seen with certain chemotherapy protocols. Dry mouth puts the patient at risk of serious dental and periodontal disease and may be a permanent condition. Therefore, effective management is important and patients must be reminded of the need to adhere to their proper hygiene protocols. Fortunately, newer radiotherapy delivery techniques are resulting in less severe chronic oral dryness. Nonetheless, it remains a common and troubling side-effect of cancer therapy. The entire dental team has a role to play in effectively managing the dry mouth cancer patient. BC Cancer - Vancouver BC Cancer - Surrey BC Cancer - Kelowna BC Cancer – Prince George 600 West 10th Avenue 19750 96th Avenue 399 Royal Avenue 1215 Lethbridge Street Vancouver, B.C. V5Z 4E6 Surrey, B.C. V3V 1Z2 Kelowna, B.C. V1Y 5L3 Prince George, B.C.
Load more

Recommended publications
  • Multiplesclerosis Associated with Trismus
    Postgrad Med J: first published as 10.1136/pgmj.66.780.853 on 1 October 1990. Downloaded from Postgrad Med J (1990) 66, 853 - 854 © The Fellowship of Postgraduate Medicine, 1990 Multiple sclerosis associated with trismus D.F. D'Costa, A.K. Vania and P.A. Millac Department ofNeurology, Leicester RoyalInfirmary, Leicester LEI 5WW, UK. Summary: This report describes the case history of a middle-aged lady who presented with symptoms and signs over one year leading to a diagnosis of multiple sclerosis. During one of her relapses, she developed trismus - an association that has not been described before in multiple sclerosis. Introduction Trismus has not been described as an association in ination there was bilateral internuclear ophthal- multiple sclerosis (MS) in standard texts on MS.1'2 moplegia (INO), spasm ofthejaw with difficulty in A possible case ofMS is mentioned in a series of 15 opening the mouth. There was a brisk jaw jerk, a patients with trismus.3 We report a patient with MS pronounced snout reflex and a palmomental reflex. who developed trismus. The CSF showed oligoclonal bands. A diagnosis of demyelination was made. She was treated with baclofen and pulsed steroids and there followed a Case report steady recovery with complete resolution of the trismus and other symptoms. by copyright. A 54 year old woman presented with an abrupt onset of bilateral ptosis and hesitancy of micturi- tion following a sore throat. She had a left mastec- Discussion tomy and radiotherapy for carcinoma 3 years earlier. On examination she had had bilateral ptosis Trismus signifies a maintained muscular spasm with normal pupillary responses and eye move- tending to close thejaws.
    [Show full text]
  • Guillain-Barre Syndrome After Generalized Tetanus Infection
    CASE REPORT Ann Clin Neurophysiol 2017;19:64-67 https://doi.org/10.14253/acn.2017.19.1.64 ANNALS OF CLINICAL NEUROPHYSIOLOGY Guillain-Barre syndrome after generalized tetanus infection Seon Jae Im1, Yun Su Hwang1, Hyun Young Park1, Jin Sung Cheong1, Hak Seung Lee1, and Jae Hoon Lee2 1Department of Neurology, Wonkwang University School of Medicine, Institute of Wonkwang Medical Science and Regional Cardiocerebrovascular Center, Iksan, Korea 2Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea Guillain-Barre syndrome (GBS) is an auto-immune disease of peripheral nerve system. It occurs Received: July 14, 2016 mainly after preceding infection such as upper respiratory or gastrointestinal infection and Revised: November 2, 2016 other antecedent events as tetanus vaccinations. However, any case of GBS after tetanus in- Accepted: November 15, 2016 fection has not been reported. Recently, when analyzed the clinical aspects of 13 tetanus pa- tients including ours, 2 GBS occurred after tetanus infection. We report the neurological and electrophysiologic findings of two cases of Guillain-Barre Syndrome after generalized tetanus. Key words: Autoimmune diseases; Guillain-Barre syndrome; Tetanus Correspondence to Guillain-Barre syndrome (GBS) is an autoimmune disease resulting in peripheral nerve de- Hyun Young Park Department of Neurology, Wonkwang struction from autoantibodies and rapidly evolving polyneuropathy, typically presenting 1,2 University School of Medicine, Institute of with limb muscle weakness, paresthesia,
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • FOI 19-459 Shingles
    Case Series Drug Analysis Print Name: FOI 19-459 Shingles DAP Report Run Date: 08-Oct-2019 Data Lock Date: 07-Oct-2019 19:00:04 Earliest Reaction Date: 09-Feb-2006 MedDRA Version: MedDRA 22.0 FOI 19-459 Shingles Shingles vaccine Drug Analysis Print. All UK DAP: spontaneous suspected shingles vaccine cases received up to and including the 7th October 2019. Report Run Date: 08-Oct-2019, Page 1 Case Series Drug Analysis Print Name: FOI 19-459 Shingles DAP Report Run Date: 08-Oct-2019 Data Lock Date: 07-Oct-2019 19:00:04 Earliest Reaction Date: 09-Feb-2006 MedDRA Version: MedDRA 22.0 Reaction Name Total Fatal Blood disorders Anaemias haemolytic immune Autoimmune haemolytic anaemia 1 0 Leukocytoses NEC Neutrophilia 1 0 Leukopenias NEC Lymphopenia 1 0 Lymphatic system disorders NEC Lymph node pain 2 0 Lymphadenopathy 9 0 Neutropenias Neutropenia 1 0 Thrombocytopenias Immune thrombocytopenic purpura 1 0 Thrombocytopenia 1 0 Blood disorders SOC TOTAL 17 0 Report Run Date: 08-Oct-2019, Page 2 Case Series Drug Analysis Print Name: FOI 19-459 Shingles DAP Report Run Date: 08-Oct-2019 Data Lock Date: 07-Oct-2019 19:00:04 Earliest Reaction Date: 09-Feb-2006 MedDRA Version: MedDRA 22.0 Reaction Name Total Fatal Cardiac disorders Cardiac signs and symptoms NEC Palpitations 8 0 Cardiomyopathies Cardiomyopathy 1 0 Coronary artery disorders NEC Arteriosclerosis coronary artery 1 0 Coronary artery disease 1 0 Heart failures NEC Cardiac failure 1 0 Ischaemic coronary artery disorders Acute myocardial infarction 1 1 Myocardial infarction 2 2 Rate and rhythm
    [Show full text]
  • Parotid Sialolithiasis and Sialadenitis in a 3-Year-Old Child
    Ahmad Tarmizi et al. Egyptian Pediatric Association Gazette (2020) 68:29 Egyptian Pediatric https://doi.org/10.1186/s43054-020-00041-z Association Gazette CASE REPORT Open Access Parotid sialolithiasis and sialadenitis in a 3- year-old child: a case report and review of the literature Nur Eliana Ahmad Tarmizi1, Suhana Abdul Rahim2, Avatar Singh Mohan Singh2, Lina Ling Chooi2, Ong Fei Ming2 and Lum Sai Guan1* Abstract Background: Salivary gland calculi are common in adults but rare in the paediatric population. It accounts for only 3% of all cases of sialolithiasis. Parotid ductal calculus is rare as compared to submandibular ductal calculus. Case presentation: A 3-year-old boy presented with acute painful right parotid swelling with pus discharge from the Stensen duct. Computed tomography revealed calculus obstructing the parotid duct causing proximal ductal dilatation and parotid gland and masseter muscle oedema. The child was treated with conservative measures, and subsequently the swelling and calculus resolved. Conclusions: Small parotid duct calculus in children may be successfully treated with conservative measures which obviate the need for surgery. We discuss the management of parotid sialolithiasis in children and conduct literature search on the similar topic. Keywords: Sialolithiasis, Sialadenitis, Salivary calculi, Parotid gland, Salivary ducts, Paediatrics Background performing computed tomography (CT) of the neck. Sialolithiasis is an obstructive disorder of salivary ductal The unusual presentation, CT findings and its subse- system caused by formation of stones within the salivary quent management were discussed. gland or its excretory duct [1]. The resulting salivary flow obstruction leads to salivary ectasia, gland dilatation Case presentation and ascending infection [2].
    [Show full text]
  • Therapeutic Alternatives in the Management of Osteoradionecrosis of the Jaws
    Med Oral Patol Oral Cir Bucal. 2021 Mar 1;26 (2):e195-207. ORN management Journal section: Oral Surgery doi:10.4317/medoral.24132 Publication Types: Review Therapeutic alternatives in the management of osteoradionecrosis of the jaws. Systematic review Gisela CV Camolesi 1, Karem L. Ortega 2, Janaina Braga Medina 3,4, Luana Campos 5,6, Alejandro I Lorenzo Pouso 7, Pilar Gándara Vila 8, Mario Pérez Sayáns 8 1 DDS. Assistant Professor of Specialization in Oral Maxillofacial Surgery at Foundation for Scientific and Technological Devel- opment of Dentistry, University of São Paulo, Brazil 2 PhD, DDS. Department of Stomatology, School of Dentistry, University of São Paulo, Brazil 3 DDS. Department of Stomatology, School of Dentistry, University of São Paulo, Brazil 4 Division of Dentistry, Mario Covas State Hospital of Santo André, São Paulo, Brazil 5 PhD, DDS. Department of Post-graduation in Implantology, University of Santo Amaro, School of Dentistry. São Paulo, Brazil 6 Oral medicine, Brazilian Cancer Control Institute. São Paulo, Brazil 7 DDS. Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes). Faculty of Medicine and Dentistry Universidade de Santiago de Compostela, Spain 8 PhD, DDS. Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes). Faculty of Medicine and Dentistry Universi- dade de Santiago de Compostela, Spain Correspondence: Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain [email protected] Camolesi GCV, Ortega KL, Medina JB, Campos L, Lorenzo Pouso AI, Gándara Vila P, et al. Therapeutic alternatives in the management of os- Received: 03/07/2020 Accepted: 28/09/2020 teoradionecrosis of the jaws. Systematic review. Med Oral Patol Oral Cir Bucal.
    [Show full text]
  • Dental Management of the Head and Neck Cancer Patient Treated
    Dental Management of the Head and Neck Cancer Patient Treated with Radiation Therapy By Carol Anne Murdoch-Kinch, D.D.S., Ph.D., and Samuel Zwetchkenbaum, D.D.S., M.P.H. pproximately 36,540 new cases of oral cavity and from radiation injury to the salivary glands, oral mucosa pharyngeal cancer will be diagnosed in the USA and taste buds, oral musculature, alveolar bone, and this year; more than 7,880 people will die of this skin. They are clinically manifested by xerostomia, oral A 1 disease. The vast majority of these cancers are squamous mucositis, dental caries, accelerated periodontal disease, cell carcinomas. Most cases are diagnosed at an advanced taste loss, oral infection, trismus, and radiation dermati- stage: 62 percent have regional or distant spread at the tis.4 Some of these effects are acute and reversible (muco- time of diagnosis.2 The five-year survival for all stages sitis, taste loss, oral infections and xerostomia) while oth- combined is 61 percent.1 Localized tumors (Stage I and II) ers are chronic (xerostomia, dental caries, accelerated can usually be treated surgically, but advanced cancers periodontal disease, trismus, and osteoradionecrosis.) (Stage III and IV) require radiation with or without che- Chemotherapeutic agents may be administered as an ad- motherapy as adjunctive or definitive treatment.1 See Ta- junct to RT. Patients treated with multimodality chemo- ble 1.3 Therefore, most patients with oral cavity and pha- therapy and RT may be at greater risk for oral mucositis ryngeal cancer receive head and neck radiation therapy and secondary oral infections such as candidiasis.
    [Show full text]
  • Pilocarpine (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Pilocarpine (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Salagen Brand Names: Canada JAMP Pilocarpine; M-Pilocarpine; Salagen What is this drug used for? It is used to treat dry mouth. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to pilocarpine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Asthma, glaucoma, liver disease, or swelling in parts of the eye. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure Pilocarpine (Systemic) 1/6 that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
    [Show full text]
  • Orofacial Manifestations of COVID-19: a Brief Review of the Published Literature
    CRITICAL REVIEW Oral Pathology Orofacial manifestations of COVID-19: a brief review of the published literature Esam HALBOUB(a) Abstract: Coronavirus disease 2019 (COVID-19) has spread Sadeq Ali AL-MAWERI(b) exponentially across the world. The typical manifestations of Rawan Hejji ALANAZI(c) COVID-19 include fever, dry cough, headache and fatigue. However, Nashwan Mohammed QAID(d) atypical presentations of COVID-19 are being increasingly reported. Saleem ABDULRAB(e) Recently, a number of studies have recognized various mucocutaneous manifestations associated with COVID-19. This study sought to (a) Jazan University, College of Dentistry, summarize the available literature and provide an overview of the Department of Maxillofacial Surgery and potential orofacial manifestations of COVID-19. An online literature Diagnostic Sciences, Jazan, Saudi Arabia. search in the PubMed and Scopus databases was conducted to retrieve (b) AlFarabi College of Dentistry and Nursing, the relevant studies published up to July 2020. Original studies Department of Oral Medicine and published in English that reported orofacial manifestations in patients Diagnostic Sciences, Riyadh, Saudi Arabia. with laboratory-confirmed COVID-19 were included; this yielded 16 (c) AlFarabi College of Dentistry and Nursing, articles involving 25 COVID-19-positive patients. The results showed a Department of Oral Medicine and Diagnostic Sciences, Riyadh, Saudi Arabia. marked heterogeneity in COVID-19-associated orofacial manifestations. The most common orofacial manifestations were ulcerative lesions, (d) AlFarabi College of Dentistry and Nursing, Department of Restorative Dental Sciences, vesiculobullous/macular lesions, and acute sialadentitis of the parotid Riyadh, Saudi Arabia. gland (parotitis). In four cases, oral manifestations were the first signs of (e) Primary Health Care Corporation, Madinat COVID-19.
    [Show full text]
  • Malignant Transformation of Oral Leukoplakia: a Multicentric Retrospective Study in Brazilian Population
    Med Oral Patol Oral Cir Bucal. 2021 May 1;26 (3):e292-8. Malignant transformation and oral leukoplakia Journal section: Oral Cancer and Potentially malignant disorders doi:10.4317/medoral.24175 Publication Types: Research Malignant transformation of oral leukoplakia: a multicentric retrospective study in Brazilian population João Mateus Mendes Cerqueira 1,2, Flávia Sirotheau Corrêa Pontes 2, Alan Roger Santos-Silva 1, Oslei Paes de Almeida 1, Rafael Ferreira e Costa 3, Felipe Paiva Fonseca 3, Ricardo Santiago Gomez 3, Nicolau Conte Neto 2, Ligia Akiko Ninokata Miyahara 1,2, Carla Isabelly Rodrigues-Fernandes 1, Elieser de Melo Galvão Neto 2, Anna Luíza Damaceno Araújo 1, Márcio Ajudarte Lopes 1, Hélder Antônio Rebelo Pontes 1,2 1 Oral Diagnosis Department (Pathology and Semiology), Piracicaba Dental School, University of Campinas, Piracicaba, Brazil 2 Service of Oral Pathology, João de Barros Barreto University Hospital, Federal University of Pará, Belém, Brazil 3 Department of Oral Surgery and Pathology, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil Correspondence: Department of Surgery and Oral Pathology João de Barros Barreto University Hospital Mundurucus Street, nº 4487 Zip Code 66073-000, Belém, Pará, Brazil [email protected] Received: 19/07/2020 Cerqueira JMM, Pontes FSC, Santos-Silva AR, Almeida OPd, Costa RF, Accepted: 28/10/2020 Fonseca FP, et al. Malignant transformation of oral leukoplakia: a multi- centric retrospective study in Brazilian population. Med Oral Patol Oral Cir Bucal. 2021 May 1;26 (3):e292-8. Article Number:24175 http://www.medicinaoral.com/ © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946 eMail: [email protected] Indexed in: Science Citation Index Expanded Journal Citation Reports Index Medicus, MEDLINE, PubMed Scopus, Embase and Emcare Indice Médico Español Abstract Background: Among the oral potentially malignant disorders, leukoplakia stands out as the most prevalent.
    [Show full text]
  • Importance of Laboratory Confirmation of Mumps Suspects
    Volume 17, Issue 7 November/December 2009 Importance of Laboratory Confirmation of Mumps Suspects Kristin Ryker, MPH ISDH Vaccine-Preventable Disease Epidemiologist The Indiana State Department of Health (ISDH) investigates several cases of suspected mumps each year. Page However, infections caused by many organisms can Article No. present with the same symptoms as mumps virus. Most Importance of Laboratory sporadic mumps suspects can be ruled out with attention Confirmation of Mumps to the clinical case definition of mumps and appropriate Suspects 1 laboratory testing. December 2009 I-NEDSS Update 4 Clinical Case Definition Indiana Tuberculosis The clinical case definition for mumps requires an illness Annual Summary 2008 6 with acute onset of unilateral or bilateral tender, self- limited swelling of the parotid and/or other salivary Tetanus 12 gland(s) [http://www.cdc.gov/mumps/clinical/qa- physical-complic.html], lasting at least 2 days, and The Facts on Christmas without other apparent cause. Clinically compatible Plants 15 illnesses (such as aseptic meningitis, encephalitis, or orchitis) may also be caused by mumps virus. Since Training Room 16 mumps disease can be difficult to clinically diagnose and be a potentially serious condition, it is essential to Data Reports 17 confirm mumps virus through appropriate laboratory testing. HIV Summary 17 Disease Reports 18 Laboratory Testing Laboratory criteria for confirmation of mumps include: • Isolation of mumps virus from a clinical specimen, or • Detection of mumps nucleic acid through polymerase chain reaction (PCR), or • Detection of mumps IgM antibody, or • Demonstration of specific mumps antibody response in absence of recent vaccination, either a four-fold increase in IgG titer as measured by quantitative assays, or a seroconversion from negative to positive using a standard serologic assay of paired acute and convalescent serum specimens.
    [Show full text]
  • Predictors of Osteoradionecrosis Following Irradiated Tooth Extraction
    Khoo et al. Radiat Oncol (2021) 16:130 https://doi.org/10.1186/s13014-021-01851-0 RESEARCH Open Access Predictors of osteoradionecrosis following irradiated tooth extraction Szu Ching Khoo1, Syed Nabil1, Azizah Ahmad Fauzi2, Siti Salmiah Mohd Yunus1, Wei Cheong Ngeow3 and Roszalina Ramli1* Abstract Background: Tooth extraction post radiotherapy is one of the most important risk factors of osteoradionecrosis of the jawbones. The objective of this study was to determine the predictors of osteoradionecrosis (ORN) which were associated with a dental extraction post radiotherapy. Methods: A retrospective analysis of medical records and dental panoramic tomogram (DPT) of patients with a history of head and neck radiotherapy who underwent dental extraction between August 2005 to October 2019 was conducted. Results: Seventy-three patients fulflled the inclusion criteria. 16 (21.9%) had ORN post dental extraction and 389 teeth were extracted. 33 sockets (8.5%) developed ORN. Univariate analyses showed signifcant associations with ORN for the following factors: tooth type, tooth pathology, surgical procedure, primary closure, target volume, total dose, timing of extraction post radiotherapy, bony changes at extraction site and visibility of lower and upper cortical line of mandibular canal. Using multivariate analysis, the odds of developing an ORN from a surgical procedure was 6.50 (CI 1.37–30.91, p 0.02). Dental extraction of more than 5 years after radiotherapy and invisible upper cortical line of mandibular canal= on the DPT have the odds of 0.06 (CI 0.01–0.25, p < 0.001) and 9.47 (CI 1.61–55.88, p 0.01), respectively.
    [Show full text]